{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:25:52Z","timestamp":1791429952792,"version":"4.3.3"},"reference-count":109,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Norwegian Financial Mechanism 2014\u20132021","award":["2020\/37\/K\/NZ7\/02387"],"award-info":[{"award-number":["2020\/37\/K\/NZ7\/02387"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Coronavirus (CoV) diseases, including Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) have gained in importance worldwide, especially with the current COVID-19 pandemic caused by SARS-CoV-2. Due to the huge global demand, various types of vaccines have been developed, such as more traditional attenuated or inactivated viruses, subunit and VLP-based vaccines, as well as novel DNA and RNA vaccines. Nonetheless, emerging new COVID-19 variants are necessitating continuous research on vaccines, including these produced in plants, either via stable expression in transgenic or transplastomic plants or transient expression using viral vectors or agroinfection. Plant systems provide low cost, high scalability, safety and capacity to produce multimeric or glycosylated proteins. To date, from among CoVs antigens, spike and capsid proteins have been produced in plants, mostly using transient expression systems, at the additional advantage of rapid production. Immunogenicity of plant-produced CoVs proteins was positively evaluated after injection of purified antigens. However, this review indicates that plant-produced CoVs proteins or their carrier-fused immunodominant epitopes can be potentially applied also as mucosal vaccines, either after purification to be administered to particular membranes (nasal, bronchus mucosa) associated with the respiratory system, or as oral vaccines obtained from partly processed plant tissue.<\/jats:p>","DOI":"10.3390\/vaccines10020138","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T22:47:32Z","timestamp":1642546052000},"page":"138","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Plant-Based Vaccines in Combat against Coronavirus Diseases"],"prefix":"10.3390","volume":"10","author":[{"given":"Benita","family":"Ortega-Berlanga","sequence":"first","affiliation":[{"name":"Institute of Plant Genetics, Polish Academy of Sciences, Strzeszy\u0144ska 34, 60-479 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5754-483X","authenticated-orcid":false,"given":"Tomasz","family":"Pniewski","sequence":"additional","affiliation":[{"name":"Institute of Plant Genetics, Polish Academy of Sciences, Strzeszy\u0144ska 34, 60-479 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: Genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An Overview of Their Replication and Pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1128\/JVI.02501-05","article-title":"Ultrastructure and Origin of Membrane Vesicles Associated with the Severe Acute Respiratory Syndrome Coronavirus Replication Complex","volume":"80","author":"Snijder","year":"2006","journal-title":"J. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"20503","DOI":"10.2807\/ese.18.24.20503-en","article-title":"Transmission scenarios for middle east respiratory syndrome coronavirus (MERS-CoV) and how to tell them apart","volume":"18","author":"Cauchemez","year":"2013","journal-title":"Euro. Surveill."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1213\/ANE.0000000000004845","article-title":"Coronaviruses and SARS-CoV-2: A Brief Overview","volume":"30","author":"Ludwig","year":"2020","journal-title":"Anesth. Analg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"Tian","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2013.10.013","article-title":"Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS","volume":"101","author":"Drexler","year":"2014","journal-title":"Antiviral Res."},{"key":"ref_8","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_9","unstructured":"(2021, November 30). Weekly Epidemiological Update on COVID-19\u201430 November 2021. Available online: https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---30-November-2021."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0065-3527(06)66005-3","article-title":"The molecular biology of coronaviruses","volume":"66","author":"Masters","year":"2006","journal-title":"Adv. Virus Res."},{"key":"ref_11","first-page":"57","article-title":"The coronavirus replicase","volume":"287","author":"Ziebuhr","year":"2005","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virusres.2014.07.024","article-title":"Coronavirus virulence genes with main focus on SARS-CoV envelope gene","volume":"194","author":"Usera","year":"2014","journal-title":"Virus Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1099\/vir.0.80671-0","article-title":"Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E","volume":"86","author":"Nal","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jsb.2010.11.021","article-title":"A structural analysis of M protein in coronavirus assembly and morphology","volume":"174","author":"Neuman","year":"2011","journal-title":"J. Struct. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1128\/JVI.01467-06","article-title":"A Severe Acute Respiratory Syndrome Coronavirus That Lacks the E Gene Is Attenuated In Vitro and In Vivo","volume":"81","author":"Rejas","year":"2007","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbrc.2020.03.047","article-title":"Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection","volume":"526","author":"Luan","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"eaal3653","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4155\/tde-2020-0035","article-title":"COVID-19 pandemic: An overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics","volume":"11","author":"Amawi","year":"2020","journal-title":"Ther. Deliv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: Initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"ref_24","first-page":"9","article-title":"Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures","volume":"53","author":"Khamitov","year":"2008","journal-title":"Vopr. Virusol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41423-020-0374-2","article-title":"Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein","volume":"17","author":"Xia","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbrc.2004.05.046","article-title":"Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein","volume":"319","author":"Yuan","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00635-20","DOI":"10.1128\/JVI.00635-20","article-title":"Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity","volume":"94","author":"Zhu","year":"2020","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.4155\/fmc-2020-0180","article-title":"Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics","volume":"12","author":"Vanpatten","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: An old drug against today\u2019s diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbrc.2005.05.089","article-title":"A human SARS-CoV neutralizing antibody against epitope on S2 protein","volume":"333","author":"Duan","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.1073\/pnas.1510830112","article-title":"Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection","volume":"112","author":"Pascal","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12123","DOI":"10.1073\/pnas.0701000104","article-title":"Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies","volume":"104","author":"Zhu","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_34","first-page":"E002","article-title":"Potential antiviral therapeutics for 2019 Novel Coronavirus","volume":"43","author":"Li","year":"2020","journal-title":"Chinese J. Tuberc. Respir. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1128\/MMBR.69.4.635-664.2005","article-title":"Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus","volume":"69","author":"Weiss","year":"2005","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/cei.13295","article-title":"Emerging viruses and current strategies for vaccine intervention","volume":"196","author":"Afrough","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1016\/S2214-109X(18)30346-2","article-title":"Estimating the cost of vaccine development against epidemic infectious diseases: A cost minimisation study","volume":"6","author":"Gouglas","year":"2018","journal-title":"Lancet Glob. Health"},{"key":"ref_38","first-page":"1969","article-title":"Developing Covid-19 vaccines at pandemic speed","volume":"31","author":"Hunter","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.chom.2020.04.021","article-title":"The Challenges of Vaccine Development against a New Virus during a Pandemic","volume":"27","author":"Diamond","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.cell.2020.06.035","article-title":"A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS","volume":"182","author":"Dai","year":"2020","journal-title":"Cell."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.chom.2020.08.002","article-title":"Approaches and Challenges in SARS-CoV-2 Vaccine Development","volume":"28","author":"Dagotto","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ahmed, S.F., Quadeer, A.A., and McKay, M.R. (2020). Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses, 12.","DOI":"10.1101\/2020.02.03.933226"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.3389\/fimmu.2020.589833","article-title":"Adjuvants for coronavirus vaccines","volume":"11","author":"Liang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.vaccine.2014.04.016","article-title":"Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice","volume":"32","author":"Coleman","year":"2014","journal-title":"Vaccine."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lan, J., Deng, Y., Chen, H., Lu, G., Wang, W., Guo, X., Lu, Z., Gao, G.F., and Tan, W. (2014). Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0112602"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Moderbacher","year":"2020","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"eabi5246","DOI":"10.1126\/sciadv.abi5246","article-title":"Protection of K18-hACE2 mice and ferrets against SARS-CoV-2 challenge by a single-dose mucosal immunization with a parainfluenza virus 5-based COVID-19 vaccine","volume":"7","author":"An","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"Lambe","year":"2020","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"ref_53","first-page":"269","article-title":"Vaccines Through Centuries: Major Cornerstones of Global Health","volume":"3","author":"Chams","year":"2015","journal-title":"Front. Public Health"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/ni.2039","article-title":"Immunological mechanisms of vaccination","volume":"12","author":"Pulendran","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","article-title":"Understanding modern-day vaccines: What you need to know","volume":"50","author":"Vetter","year":"2018","journal-title":"Ann. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/CMR.00005-06","article-title":"Emerging respiratory viruses: Challenges and vaccine strategies","volume":"19","author":"Subbarao","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_57","first-page":"25","article-title":"Immune-informatic analysis and design of peptide vaccine from multi-epitopes against Corynebacterium pseudotuberculosis","volume":"12","author":"Franceschi","year":"2018","journal-title":"Bioinform. Biol. Insights"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"12288","DOI":"10.1073\/pnas.1402981111","article-title":"Vaccines, new opportunities for a new society","volume":"111","author":"Rappuoli","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0264-410X(99)00351-5","article-title":"HPV6b virus like particles are potent immunogens without adjuvant in man","volume":"18","author":"Zhang","year":"2000","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.coviro.2013.02.001","article-title":"Novel vaccine strategies against emerging viruses","volume":"3","author":"Mena","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/cei.13287","article-title":"Novel approaches for the design, delivery and administration of vaccine technologies","volume":"196","author":"Wallis","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1016\/j.vaccine.2017.02.015","article-title":"Vaccine development for emerging virulent infectious diseases","volume":"35","author":"Maslow","year":"2017","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1002\/jmv.26924","article-title":"Nucleoside-modified messenger RNA COVID-19 vaccine platform","volume":"93","author":"Roncati","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.biotechadv.2010.11.004","article-title":"Advances in plant molecular farming","volume":"29","author":"Obembe","year":"2011","journal-title":"Biotechnol. Adv."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.tibtech.2003.10.002","article-title":"Molecular farming in plants: Host systems and expression technology","volume":"21","author":"Twyman","year":"2003","journal-title":"Trends Biotechnol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1387-2656(07)13006-4","article-title":"Pharming and transgenic plants","volume":"13","author":"Lienard","year":"2007","journal-title":"Biotechnol. Annu. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0958-1669(00)00244-5","article-title":"Transgenic plants as protein factories","volume":"12","author":"Giddings","year":"2001","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1023\/A:1008975123362","article-title":"Molecular farming of pharmaceutical proteins","volume":"9","author":"Fischer","year":"2000","journal-title":"Transgenic Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/pbi.12428","article-title":"Large-scale production of pharmaceutical proteins in plant cell culture-the protalix experience","volume":"13","author":"Tekoah","year":"2015","journal-title":"Plant Biotechnol. J."},{"key":"ref_70","first-page":"275","article-title":"Overview of Plant-based Vaccines","volume":"10","author":"Naderi","year":"2015","journal-title":"Res. J. Fish. Hydrobiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(20)32014-6","article-title":"Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18\u201364 years) and older adults (\u226565 years): Two multicentre, randomised phase 3 trials","volume":"396","author":"Ward","year":"2020","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Shanmugaraj, B., Bulaon, C.J.I., and Phoolcharoen, W. (2020). Plant molecular farming: A viable platform for recombinant biopharmaceutical production. Plants, 9.","DOI":"10.3390\/plants9070842"},{"key":"ref_73","first-page":"831","article-title":"Recent Development and Future Prospects of Plant-Based Vaccines","volume":"18","author":"Suhail","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Moon, K.B., Park, J.S., Park, Y.I., Song, I.J., Lee, H.J., Cho, H.S., Jeon, J.H., and Kim, H.S. (2020). Development of systems for the production of plant-derived biopharmaceuticals. Plants, 9.","DOI":"10.3390\/plants9010030"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Rosales-Mendoza, S., M\u00e1rquez-Escobar, V.A., Gonz\u00e1lez-Ortega, O., Nieto-G\u00f3mez, R., and Ar\u00e9valo-Villalobos, J.I. (2020). What does plant-based vaccine technology offer to the fight against COVID-19?. Vaccines, 8.","DOI":"10.3390\/vaccines8020183"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00299-004-0767-1","article-title":"Plant molecular farming: Systems and products","volume":"22","author":"Horn","year":"2004","journal-title":"Plant Cell Rep."},{"key":"ref_77","first-page":"4928637","article-title":"Plant-based vaccines: Production and challenges","volume":"2016","author":"Laere","year":"2016","journal-title":"J. Bot."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.vaccine.2005.01.006","article-title":"Magnifection\u2014A new platform for expressing recombinant vaccines in plants","volume":"23","author":"Gleba","year":"2005","journal-title":"Vaccine"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.virol.2008.08.022","article-title":"Development of a new cucumber mosaic virus-based plant expression vector with truncated 3a movement protein","volume":"381","author":"Fujiki","year":"2008","journal-title":"Virology"},{"key":"ref_80","unstructured":"(2021, November 30). COVID-19 Vaccine Tracker and Landscape. Available online: https:\/\/www.who.int\/publications\/m\/item\/draft-landscape-of-covid-19-candidate-vaccines."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1177\/153537020623100808","article-title":"Accumulation of recombinant SARS-CoV spike protein in plant cytosol and chloroplasts indicate potential for development of plant-derived oral vaccines","volume":"231","author":"Li","year":"2006","journal-title":"Exp. Biol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1016\/j.vaccine.2009.05.073","article-title":"Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice","volume":"27","author":"Zheng","year":"2009","journal-title":"Vaccine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1073\/pnas.0503760102","article-title":"Severe Acute Respiratory Syndrome (SARS) S Protein Production in Plants","volume":"102","author":"Pogrebnyak","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7774\/cevr.2021.10.1.13","article-title":"Current updates and research on plant-based vaccines for coronavirus disease 2019","volume":"10","author":"Kumar","year":"2021","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Maharjan, P.M., and Choe, S. (2021). Plant-based COVID-19 vaccines: Current status, design, and development strategies of candidate vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9090992"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Shanmugaraj, B., Siriwattananon, K., Malla, A., and Phoolcharoen, W. (2021). Potential for developing plant-derived candidate vaccines and biologics against emerging coronavirus infections. Pathogens, 10.","DOI":"10.3390\/pathogens10081051"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1146\/annurev-arplant-043015-111812","article-title":"Antibody Production in Plants and Green Algae","volume":"67","author":"Yusibov","year":"2016","journal-title":"Annu. Rev. Plant Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e1587","DOI":"10.1002\/wnan.1587","article-title":"Plant molecular farming of virus-like nanoparticles as vaccines and reagents","volume":"12","author":"Rybicki","year":"2020","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.virol.2012.09.014","article-title":"A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles","volume":"435","author":"Blokhina","year":"2013","journal-title":"Virology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1134\/S0026893316040099","article-title":"The true story and advantages of the famous Hepatitis B virus core particles","volume":"50","author":"Pumpens","year":"2016","journal-title":"Mol. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-1-4939-7808-3_7","article-title":"Recombinant expression of tandem-HBc virus-like particles (VLPs)","volume":"1776","author":"Stephen","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/pbi.12076","article-title":"A method for rapid production of heteromultimeric protein complexes in plants: Assembly of protective bluetongue virus-like particles","volume":"11","author":"Thuenemann","year":"2013","journal-title":"Plant Biotechnol. J."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Zahmanova, G., Mazalovska, M., Takova, K., Toneva, V., Minkov, I., Peyret, H., and Lomonossoff, G. (2021). Efficient production of chimeric hepatitis b virus-like particles bearing an epitope of hepatitis e virus capsid by transient expression in Nicotiana benthamiana. Life, 11.","DOI":"10.3390\/life11010064"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"7679","DOI":"10.1038\/s41598-017-08247-9","article-title":"Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_96","first-page":"33","article-title":"Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein","volume":"77","author":"Ravin","year":"2012","journal-title":"Biochemistry"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/hyb.2008.0008","article-title":"Plant-produced hepatitis B core protein chimera carrying anthrax protective antigen domain-4","volume":"27","author":"Bandurska","year":"2008","journal-title":"Hybridoma"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Kesik-Brodacka, M., Lipiec, A., Kozak Ljunggren, M., Jedlina, L., Miedzinska, K., Mikolajczak, M., Plucienniczak, A., Legocki, A.B., and Wedrychowicz, H. (2017). Immune response of rats vaccinated orally with various plant-expressed recombinant cysteine proteinase constructs when challenged with Fasciola hepatica metacercariae. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005451"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11248-007-9135-6","article-title":"Immunogenicity of recombinant hepatitis B virus surface antigen fused with preS1 epitopes expressed in rice seeds","volume":"17","author":"Qian","year":"2008","journal-title":"Transgenic Res."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Mati\u0107, S., Rinaldi, R., Masenga, V., and Noris, E. (2011). Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnol., 11.","DOI":"10.1186\/1472-6750-11-106"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3109\/13880209.2015.1048371","article-title":"Co-expression of hepatitis C virus polytope-HBsAg and p19-silencing suppressor protein in tobacco leaves","volume":"54","author":"Mohammadzadeh","year":"2016","journal-title":"Pharm. Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.addr.2018.08.007","article-title":"Use of plant viruses and virus-like particles for the creation of novel vaccines","volume":"145","author":"Balke","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3389\/fpls.2019.00803","article-title":"Plant viruses in plant molecular pharming: Toward the use of enveloped viruses","volume":"10","author":"Ibrahim","year":"2019","journal-title":"Front. Plant Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00299-016-2088-6","article-title":"Expression of an immunogenic LTB-based chimeric protein targeting Zaire ebolavirus epitopes from GP1 in plant cells","volume":"36","author":"Angulo","year":"2017","journal-title":"Plant Cell Rep."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Randall, T.D. (2010). Bronchus-Associated Lymphoid Tissue (BALT). Structure and Function, Elsevier Inc.. [1st ed.].","DOI":"10.1016\/B978-0-12-381300-8.00007-1"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1016\/j.vaccine.2015.07.022","article-title":"Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-Structure, function and species differences","volume":"33","author":"Pabst","year":"2015","journal-title":"Vaccine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2017.04.008","article-title":"Current state and challenges in developing oral vaccines","volume":"114","author":"Sharpe","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2017.07.004","article-title":"History and mechanisms of oral tolerance","volume":"30","author":"Rezende","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1016\/j.vaccine.2018.09.006","article-title":"Plant lyophilisate carrying S-HBsAg as an oral booster vaccine against HBV","volume":"36","author":"Pniewski","year":"2018","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/138\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:03:06Z","timestamp":1760133786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/2\/138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":109,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["vaccines10020138"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10020138","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]}}}